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Abstract
Background: Lymphatic filariasis (LF) control in most countries of sub-Saharan Africa is based on annual mass drug
administration (MDA) with a combination of ivermectin and albendazole, in order to interrupt transmission. However,
attaining and maintaining high treatment coverage has been a challenge in many LF control programmes. This study
was designed to elucidate reasons for continued transmission of LF in an endemic area of Tanga, northeastern
Tanzania, where control activities based on MDA had been in place for eight years by the time of this study in 2012.
Methods: A cross-sectional questionnaire survey was conducted in three sentinel villages used for monitoring the
impact of MDA on LF transmission. A total of 747 individuals were interviewed, out of which 172 (23.0%), 27 (3.6%)
and 49 (6.5%) had been shown to have circulating filarial antigens (CFA), microfilaraemia (MF) and LF gross lesions,
respectively, prior to the interviews.
Results: The interviewed population had a mean age of 33.7 years and a male to female ratio of 0.8. Males, individuals
aged 30 years and above, peasants/fishermen and recent immigrants to the study communities were significantly more
affected (CFA, MF and/ or LF gross lesions) than the other population groups. However, drug uptake rates were not
significantly different between LF affected (those with CFA, MF and/ or LF gross lesions) and non-affected individuals.
Likewise, drug uptake rates were not significantly different across different demographic parameters of the study
population, some of which differed significantly in the level of infection. Moreover, it was found that misconceptions
on how LF can be acquired were still evident, linking its transmission to witchcraft, heredity and sexual behaviour.
Conclusions: The findings indicated that misconceptions about LF and its transmission still existed despite eight years of
control activities in the area. Improved communication on the rationale of MDA and an enhanced drug delivery strategy
that is adapted to the local settings and targeting important demographic groups that serve as reservoir of infection will
help in reaching the elimination target within a reasonable timeframe.
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Background
Lymphatic filariasis (LF) is a major public health prob-
lem in many developing countries and one of the most
prevalent of the neglected tropical diseases (NTDs) [1].
In sub-Saharan Africa, LF is caused by Wuchereria
bancrofti and transmitted by Anopheles and Culex
mosquitoes [2]. In this region, it has been estimated that
more than 45 million people are affected by LF [3]. The
disease has considerable mental and socio-economic con-
sequences to the affected individuals, and has been ranked
as a leading cause of long-term disability in the world [4].
LF is widespread in Tanzania where it has been estimated
that nearly six million people live with debilitating mani-
festations of the disease [5].
LF was targeted for global elimination following a World
Health Assembly resolution passed in 1997, and subse-
quently in 2000 the World Health Organization (WHO)
launched the Global Programme to Eliminate Lymphatic
Filariasis (GPELF) with a target of eliminating the disease
by 2020 [6, 7]. The principal intervention measure of
GPELF is interruption of transmission by annual mass
drug administration (MDA) of a single dose of albendazole
in combination with either diethylcarbamazine (DEC) or
ivermectin to all eligible individuals in endemic areas [8].
The drug combination reduces the density of microfilariae
in the blood and thereby the level of disease transmission
in endemic areas. However, for this strategy to be effective,
a high treatment coverage (estimated to range from 65–
90%) successively for at least five to six years (correspond-
ing to the life-span of the adult worms) is necessary [8, 9].
The MDA strategy has shown promise in LF transmis-
sion control by reducing onward transmission of the disease
in many endemic countries [10–12]. Reports have shown
that by using this strategy, some countries have managed to
lower LF transmission indices to below the cut-off thresh-
old set by the WHO for elimination [12–14]. However,
transmission of LF still continues in some areas with
ongoing MDA based control activities [10–12]. It has been
predicted that endemic areas with high baseline prevalence
and/ or presence of very efficient vectors will require
relatively higher treatment coverage (at least 90%) to
stop parasite transmission [9, 15]. In Ghana, 14 rounds
of MDA did not stop the transmission of LF in districts
with relatively high baseline prevalence, while control
was possible in districts with low baseline prevalence
[16]. Moreover, it has been suggested that continued
transmission of LF in control programme areas may
also be a result of lower than optimal drug uptake [11,
17]. Drug compliance has been found to be affected by
several factors including fear of side effects, a general
dislike of taking drugs, low motivation of drug distribu-
tors, lack of knowledge of the disease in question and
inadequate communication on the rationale of MDA as
previously summarized [18–20].
In Tanga district, northeastern Tanzania, seven rounds
of annual MDA were completed between October 2004
and December 2011. During this period, irregularities were
observed in the timing of MDAs (inter-MDA period longer
or shorter than one year) and drug treatment coverages
were generally on the lower side, as previously reported
[11, 21, 22]. In this respect, several studies conducted in
Tanzania have suggested the need for improved drug
uptake in the affected communities for the target of LF
elimination to be achieved [11, 17, 18]. As the deadline set
for LF elimination is approaching, all factors that affect the
effectiveness of the MDA strategy need to be elucidated
such that programmatic adjustments can be made to
achieve the target within a reasonable timeframe. The
current study was designed to elucidate the possible
reasons for the continued transmission of LF in an
endemic area of Tanga, northeastern Tanzania, where
control activities based on MDA had been in place for
eight years by 2012.
Methods
Study sites
The study was conducted in three villages located in
Tanga District in Tanga Region, northeastern Tanzania.
The villages were originally selected as sentinel sites for
monitoring the impact of MDA on LF infection and
transmission, and detailed descriptions of the sites and
findings have been reported elsewhere [11, 21–23]. In
brief, the villages were Kirare (5°15'01"S, 39°01'40"E)
located about 20 km south of Tanga city along the
Tanga-Pangani road, Kiomoni (5°04'01"S, 39°03'17"E)
located about 5 km northwest of Tanga city near the
Tanga-Amboni road, and Kisimatui (5°11'0"S, 39°0'0"E)
located about 17 km southwest of Tanga city along the
Pongwe-Marungu road. A population census conducted
by the study team in November 2011 recorded a total
of 690, 504 and 651 individuals in the included parts of
Kirare (Mashine and Mtambuuni hamlets), Kiomoni
(Mabavu hamlet) and Kisimatui (Majengo hamlet),
respectively [22].
Study design
The current study was cross-sectional and questionnaire
based. Individuals with known LF infection and chronic
disease status as determined in a survey in November
2011 (immediately before the 7th round of MDA in
December 2011) were interviewed in May 2012. In the
2011 survey, a total of 1072 individuals were examined
for LF infection of which 42 had microfilariae (MF) and
213 had circulating filarial antigens (CFA) [22]. The
methods used for diagnosing infections were described in
detail previously [22], but briefly, MF were detected by
counting chamber examination of 100 μl blood collected
after 9 p.m., while CFA were detected in blood by use of
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immunochromatographic test cards (Binax Now Filariasis,
Inverness Inc., Massachusetts, USA). Clinical examination
moreover revealed that 54 of the individuals had gross
chronic manifestations of LF (hydrocele and/or elephant-
iasis). Among the target population of 1072 individuals,
200 were excluded due to their young age (< 10 years) and
125 were lost to follow-up (Fig. 1). LF infection status in
young school-children in the same sentinel villages has
been reported previously [22, 23] and is generally low. Of
125 individuals who were lost to follow-up, 35 (28.0%), 6
(4.8%), 2 (1.6%) and 2 (1.6%) had CFA, MF, hydrocele and
elephantiasis, respectively. Thus, the remaining 747 indi-
viduals from Kirare, Kisimatui and Kiomoni were included
in the current study (Fig. 1).
Questionnaire survey
The questionnaire survey was conducted to assess and
compare characteristics of the filarial affected and non-
affected individuals, especially on their perception of LF
disease and control, and their reasons for taking or not
taking the drugs during the MDAs. The questionnaire
was prepared in English, translated into Kiswahili, pilot-
tested in the field and revised accordingly before the
actual data collection. Following the interviews, ques-
tionnaires were back-translated to English during data
entry. The questionnaire surveys were carried out in
May 2012 by trained field staff with experience in LF
surveillance. By using a prepared list of participants
(with serial number, hamlet number, house number, sex
and age), interviewers visited their households and requested
them to participate in the interviews. Although participants
were known, interviewers were unaware of the infection and
disease status of the individuals being interviewed (a blinded
interview) except for those with obviously visible lesions.
Interviewers visited a particular household at least twice to
make sure that as many as possible of the individuals in the
list were interviewed.
Data analysis
Data collected were entered in an Excel database and
transferred to SPSS (SPSS Inc., Chicago, IL, USA) for
analysis. For the analyses, respondents were categorized
in two age groups: 10–29 and ≥ 30 years. The level of
education was categorized into two groups as either “none
to not completed standard 7” or “at least completed
standard 7”. A household wealth index was calculated
based on availability of the following in a particular house-
hold: a mobile phone (1 point), a radio (2 points), a bicycle
(3 points), a television (4 points), a refrigerator (5 points),
a cow (6 points) and a motorcycle (7 points). The sum of
points were calculated and categorized into zero (low
income), 1–10 (medium income) and > 10 (high income).
Different variables were compared using a Chi-square test
and a P-value ≤ 0.05 was considered statistically significant.
Results
A total of 747 individuals were interviewed from Kirare
(37.9%), Kisimatui (32.7%) and Kiomoni (29.5%) villages.
Fig. 1 Study design
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The male to female ratio was 0.8 and the mean age of
the respondents was 33.7 years (range of 10–95 years).
Of the interviewed individuals, 172 (23.0%), 27 (3.6%) and
49 (6.5%) had CFA, MF and LF gross lesions (hydrocele
and/or elephantiasis), respectively (Fig. 1). Of the 49
respondents with LF gross lesions, 17 had elephantiasis
with 4 (23.5%) and 1 (5.9%) having CFA and MF,
respectively. Likewise, of the 49 respondents with LF
gross lesions, 33 had hydrocele with 9 (27.3%) and 2
(6.1%) having CFA and MF, respectively. One individual
had both hydrocele and elephantiasis. LF infection status
among the respondents varied considerably by demo-
graphic characteristics of the study population (Table 1).
Males and individuals aged 30 years and above were
significantly more affected (CFA, MF and/ or LF gross
lesions) than females and those below 30 years. With
Table 2 Reported drug uptake in December 2011 in relation to the demographic characteristics and LF status of the study
population (analyzed by Chi-square tests)
Characteristic No. (% of total) No. (%) reported
drug uptake
χ2-value P-value
Gender (n = 737)
Female 416 (56.4) 319 (76.7) 0.626 0.429
Male 321 (43.6) 254 (79.1)
Age group (n = 737)
10–29 years 370 (50.2) 277 (74.9) 3.569 0.059
≥ 30 years 367 (49.8) 296 (80.7)
School education (n = 737)
None or not completed Std. 7 246 (33.4) 183 (74.4) 2.406 0.121
At least completed Std. 7 491 (66.6) 390 (79.4)
Occupation (n = 737)
Pupil/student 251 (34.1) 191 (76.1) 2.270 0.321
Peasant/fisherman 298 (40.4) 240 (80.5)
Othera 188 (25.5) 142 (75.5)
Stay in village (n = 736)b
≥ 10 years 362 (49.2) 291 (80.4) 2.931 0.087
< 10 years 374 (50.8) 281 (75.1)
Wealth index (n = 737)
Low income 72 (9.8) 55 (76.4) 4.455 0.108
Medium income 494 (67.0) 375 (75.9)
High income 171 (23.2) 143 (83.6)
LF infectionc (n = 737)
Yes 170 (23.1) 129 (75.9) 0.444 0.505
No 567 (76.9) 444 (78.3)
LF mfd (n = 737)
Yes 27 (3.7) 19 (70.3) 0.882 0.348
No 710 (96.3) 554 (78.0)
LF lesione (n = 737)
Yes 49 (6.6) 38 (77.6) 0.001 0.973
No 688 (93.4) 535 (77.8)
LF infection, mf and/or lesion (n = 737)
Yes 206 (28.0) 159 (77.2) 0.052 0.819
No 531 (72.0) 414 (78.0)
aPublic/private employee, self-employed, housewife or no occupation
bOne respondent did not answer/remember
cCFA positive
dMicrofilariae positive
eHydrocele and/or elephantiasis
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respect to occupation and duration of stay in the study
villages, peasants/fishermen and recent immigrants (at
most 10 years stay in the villages) were more affected than
those engaged in other economic activities and natives
(Table 1).
Most of the respondents (94.7%, n = 698) were aware of
the ongoing MDA for LF control, but only 573 (77.7%)
participated by swallowing the drugs in the December
2011 MDA campaign. Drug uptake rates were not signifi-
cantly different between LF affected (those with CFA, MF
and/ or LF gross lesions) and non-affected individuals
(Tables 1, 2). Moreover, drug uptake rates were not differ-
ent across different demographic parameters of the study
population (Table 2).
For the 573 individuals who took the drugs, the major
reason for the uptake as reported by 469 (81.8%) respon-
dents was to prevent them from getting LF. On the
other hand, of 164 (22.3%) individuals who reported not
to have taken the drugs, 75 (45.7%) had been absent at
the time of drug distribution (Table 3).
The majority of the respondents reported that drugs
were distributed at designated central places in the villages
(59.7%, n = 423) by community health workers or mem-
bers (69.3%, n = 475). Seventy-three percent (n = 537) of
the respondents considered the methods deployed in the
drug distribution to be convenient (Table 4). Of those who
were not happy with the distribution method, some were
of the view that drugs should be given by doctors (n = 3)
and delivered at health facilities (n = 13). The reported
drug uptake was significantly higher when the drugs were
delivered to people’s homes/schools (Table 4). The reported
drug uptake was not significantly different between differ-
ent categories of distributors, although there was a trend of
an increase in reported uptake when drugs distribution
was conducted by health facility staff or village leaders.
Most of the respondents (93.3%, n = 652) were of the
view that LF is a health problem in the study villages.
However, the reported drug uptake between those who
Table 3 Reasons given for taking or not taking drugs in the
December 2011 MDA campaign
Question/answer No. of respondents (%)
Did you take the tablets in the 2011 MDA
campaign? (n = 737)
Yes 573 (77.7)
No 164 (22.3)
Why did you take the tablets? (n = 573)
Prevent getting LF 469 (81.8)
Abiding leaders’ instructions 56 (9.8)
Other benefits of the drugs 12 (2.1)
Drugs given free of charge 6 (1.0)
Other people taking the drugs 3 (0.5)
No reason given 27 (4.7)
Why you did not take the tablets? (n = 164)
Absent during the distribution 75 (45.7)
Drugs not distributed 8 (4.9)
Drugs contraindicated to me 9 (5.5)
Not informed about distribution time 27 (16.5)
Dislike the tablets 2 (1.2)
Afraid of side effects 4 (2.4)
I don’t have LF (tablets are for those with LF) 19 (11.6)
No reason given 20 (12.2)
Table 4 Responses to questions about drug distribution and
perceived community health problems, and their relation to the
reported drug uptake (analyzed by Chi-square tests)
Question/response No.
(% of
total)
No. (%)
reported
drug
uptake
χ2-value P-value
Where were the drugs
given? (n = 708)a
From a central place 423 (59.7) 327 (77.3) 20.681 < 0.001
Brought home/school 175 (24.7) 161 (92.0)
From the health
facility
110 (15.5) 81 (73.6)
Who distributed the
drugs? (n = 685)b
Community health
workers/members
475 (69.3) 378 (79.6) 1.603 0.449
Health facility staff 123 (18.0) 101 (82.1)
Village leaders 87 (12.7) 74 (85.1)
Was the distribution
method good? (n = 577)c
Yes 537 (93.1) 478 (89.0) 2.947 0.086
No 40 (6.9) 32 (80.0)
What do you consider
most important health
problem in your
community? (n = 657)d
Malaria 446 (67.9) 355 (79.6) 4.025 0.134
HIV/AIDS 123 (18.7) 91 (74.0)
LF 88 (13.4) 75 (85.2)
Do you consider LF a
health problem in your
community? (n = 699)e
Yes 652 (93.3) 506 (77.6) 0.026 0.872
No 47 (6.7) 36 (76.6)
a29 repondents who reported other minor distribution channels were excluded
b52 respondents who reported that other individuals distributed the drugs
were excluded
c141 respondents who reported that they did not know and 19 who did not
give any answer were excluded
d80 respondents were excluded [59 who reported health problems including
pneumonia (n = 27), gastro-intestinal disorders (n = 17), skin infections (n = 6),
flu (n = 4), schistosomiasis (n = 3), tuberculosis (n = 1) and high blood
pressure (n = 1), in addition to 21 who replied that they did not know]
e38 respondents who replied that they did not know were excluded
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considered LF a health problem and those of the view that
LF was not a health problem was not significantly different
(Table 4). When asked to mention important disease con-
ditions in their villages, LF ranked the third in the list after
malaria and HIV/AIDS (Table 4). The reported drug up-
take rates were not significantly different between the re-
spondents who cited malaria, HIV/AIDS or LF as the most
important disease condition (Table 4). Despite years of
control activities based on MDA, LF was still poorly under-
stood by the inhabitants in the study villages. More than
half (53.3–56.0%) of the respondents were not aware how
LF was transmitted. Furthermore, misconceptions were still
evident on how LF can be acquired, linking its transmission
to witchcraft, heredity and sexual behaviour (Table 5).
Discussion
Successful elimination of LF based on the MDA strategy
relies on maintaining a high treatment coverage to reduce
the worm burden in humans and hence the onwards trans-
mission [9, 15]. However, attaining and maintaining a high
treatment coverage has been a challenge in many LF control
programmes globally, including the Tanzanian National
Lymphatic Filariasis Elimination Programme [11, 17, 24–28].
Moreover, as the LF control campaigns progresses, the re-
peated rounds of MDA will eventually lead to fatigue among
both programme implementers and those swallowing the
drugs. It is crucial that all factors that affect effectiveness of
the MDA strategy are understood and addressed to improve
and maintain a high treatment coverage to accelerate the LF
elimination efforts. With the deadline set to achieve global
elimination of LF quickly approaching, renewed advocacy on
MDA strategies adapted to local endemic communities
needs to be intensified rather than relaxed.
The findings of the present study showed that reported
drug uptake rates were not significantly different among
those affected (with CFA, MF and/ or LF gross lesions)
and non-affected. Moreover, the reported drug uptake rates
were not significantly different across different demographic
parameters of the study population, some of which were
reservoirs of infection. Significantly more affection (CFA,
MF and/ or LF gross lesions) was recorded in males, adults
(≥ 30 years), peasants/fishermen and recently immigrated
individuals (at most 10 years stay in the village). Studies
conducted elsewhere have shown that the adult population,
particularly males and peasants/fishermen, are dispropor-
tionally more likely to be infected and are hence important
for the transmission of LF [29–31]. The reasons for high in-
fection rates detected among the recent immigrants are not
entirely clear, but we suggest that many of these individuals
may have arrived from areas with no active MDA and/or
may have been more exposed to infectious bites. MDA
non-compliance among infected individuals (with reservoirs
of worms) is of great concern as failure to treat these means
that transmission continues. In this study, people with LF
gross lesions were not found to be very important for
ongoing LF transmission as relatively few (6.0%) were
harbouring MF. Other studies have also reported high rates
of amicrofilaraemia among patients with LF gross lesions
[32, 33]. Importantly, it has also been shown elsewhere that
implementation of morbidity management programs can
have a very positive effect on MDA compliance [34].
In the villages of the present study, drugs were mainly
offered at a designated central place, and distributed by
community health workers. The majority of the respon-
dents considered the mode of drug distribution to be
convenient and appropriate. However, several individuals
Table 5 Responses to questions about individuals’ perception of the mode of acquiring LF infection and lesions (n = 747)
Response No. (% of total)
Mode of acquiring LF infection Mode of acquiring hydrocele Mode of acquiring elephantiasis
Don’t know 418 (56.0) 417 (55.8) 398 (53.3)
Mosquito bite 295 (39.5) 280 (37.5) 312 (41.8)
Stepping on unclean mattera 9 (1.2) 13 (1.7) 13 (1.7)
Living/sleeping with infected person 7 (0.9) 7 (0.9) 5 (0.7)
Sex with infected person 4 (0.5) 4 (0.5) 3 (0.4)
Sex during menstrual period 2 (0.3) 10 (1.3) 4 (0.5)
Witchcraft 2 (0.3) 2 (0.3) 6 (0.8)
Injury 2 (0.3) 2 (0.3) 2 (0.3)
Infection with parasites 3 (0.4) 2 (0.3) –
Inherited 3 (0.4) 2 (0.3) 2 (0.3)
God’s decision – – 2 (0.3)
Other causes 2b (1.9) 8c(1.1) –
aRelated to witchcraft
bWeather conditions (n = 2)
cHigh ambient temperature (n = 1), drinking coconut milk (n = 1), chronic hernia (n = 6)
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who were not comfortable with the distribution plan
were of the view that drugs should be given by doctors
or in health facilities. This point of view from a minority
in the population needs to be considered, to improve
drug uptake. Recruiting respected drug distributors
empowered with adequate training and supervision was
found to improved drug uptake rates elsewhere [35, 36].
On the other hand, major reasons reported by those who
did not take the drugs were consequent to inadequate
communication as to why people should swallow the drugs
and inappropriate delivery time when some of the commu-
nity members were not available in their respective villages
(during school vacations and crop growing/harvesting
seasons). These findings corroborate with those of others
who have analyzed factors that cause lower than optimal
treatment coverage in MDA programmes in different
endemic countries [17, 18, 26, 37].
The findings of the present study have shown that even
after several years of control activities, LF is still not well
understood by nearly half of the people living in endemic
communities, and its importance as a disease condition
ranked well below that of malaria and HIV. Even individ-
uals with gross lesions were not fully aware of the disease
etiology, and did not consider it an important disease con-
dition. Moreover, hydrocele and elephantiasis were still
considered different entities by some of the respondents.
Our findings on community perceptions on LF corrobor-
ate with those of others who have reported a variety of
misconceptions surrounding LF in endemic communities
neighbouring our study sites and elsewhere [18, 38]. It is
encouraging that only a few individuals still considered LF
a non-important disease. However, much still has to be
done to educate the local communities on LF so they feel
encouraged to participate effectively in elimination efforts.
Although reported drug uptake rates in the current
study were relatively high (77.7%) and above the level
recommended by the World Health Organization (65%
or higher) [39], our findings suggest the need for adjust-
ments in the MDA delivery. It is undisputable that a high
treatment coverage is a predictor of successful LF elimin-
ation. However, our findings indicated that the population
of LF parasite carriers in the community were treated at
the same rate as those who were not infected. Thus
continued delivery of MDA with this strategy will miss
a good proportion of infected individuals and hence
increase the duration necessary to reach the elimination
target. As done for interventions targeting other diseases,
innovation in delivering MDA is a requirement especially
at the period when fatigue is expected, due to repeated
rounds of drug uptake. We therefore suggest an enhanced
MDA strategy and delivery mechanism that specifically
targets adult males, peasants/fishermen and recent immi-
grants. To have a reasonable participation of the peasantry
community, drugs should be distributed after the
harvesting season. Drug distribution points in the fish
markets will improve uptake in the fishermen community.
Efforts should also be made to locate and treat recent im-
migrants who may not yet have proper housing or live in
farms away from the village centre. In addition to im-
proved communication, MDA needs to be tailored with
events that will attract attention of the adult male popula-
tion like sports, and MDA should be delivered by individ-
uals who are adequately trained, motivated and respected
by the community members.
Conclusions
The findings of this study suggest that misconceptions
surrounding LF disease and its transmission still exist
despite eight years of control activities. Improved com-
munication on the rationale of MDA and an enhanced
drug delivery strategy that is adapted to the local settings
and targeting important groups that serve as reservoir
of infection will help in reaching the elimination target
within a reasonable timeframe.
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